(125 days)
Not Found
No
The provided text describes a radiofrequency ablation system and its components, focusing on the delivery of RF energy and cooling mechanisms. There is no mention of AI, ML, image processing, or any other technology typically associated with AI/ML in the device description, intended use, or performance studies.
Yes.
The device is intended for palliative treatment of metastatic malignant lesions, coagulation and ablation of tissue, and ablation of benign bone tumors (osteoid osteoma), all of which are therapeutic interventions.
No
Explanation: The device is described as an "RF Ablation System" intended for "ablation of metastatic malignant lesions" and "coagulation and ablation of tissue in bone". This indicates its purpose is therapeutic, not diagnostic. It delivers energy to treat conditions, rather than identifying or characterizing them.
No
The device description explicitly lists multiple hardware components including a generator, probes, tubes, pump, connector hub, and cart, indicating it is a hardware-based system with associated software.
Based on the provided information, the OsteoCool™ RF Ablation System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly describes a therapeutic procedure performed in vivo (within the living body) to ablate tissue in bone. IVD devices are used in vitro (outside the living body) to examine specimens derived from the human body (like blood, urine, or tissue samples) to provide information for diagnosis, monitoring, or screening.
- Device Description: The description details a system that delivers energy directly to tissue within the body. It does not describe components used for analyzing biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, reagents, or any other typical components of an IVD device.
Therefore, the OsteoCool™ RF Ablation System is a therapeutic medical device, not an IVD.
N/A
Intended Use / Indications for Use
The OsteoCool™ RF Ablation System is intended for:
- Palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body.
- Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy.
- Ablation of benign bone tumors such as osteoid osteoma.
Product codes (comma separated list FDA assigned to the subject device)
GEI
Device Description
The OsteoCool™ RF Ablation System includes the following components:
- OsteoCool Radiofrequency Generator
- OsteoCool RF Ablation Kit:
i. OsteoCool RF Ablation Probe
ii. OsteoCool Tube Kit - OsteoCool Thermocouple Kit:
i. Osteocool Thermocouple Monitor
ii. Osteocool Thermocouple Monitor Introducer - Osteocool Peristaltic Pump & OsteoCool Pump Cable
- OsteoCool Connector Hub
- OsteoCool Cart
The OsteoCool™ RF Ablation System delivers controlled radiofrequency (RF) energy in a bipolar manner with a cooling mechanism to facilitate RF lesions in target tissue. The OsteoCool Radiofrequency (RF) Generator operates together with the OsteoCool RF Ablation Probe to deliver the RF energy to the target ablation site(s). The OsteoCool Tube Kit is used with the Osteocool Peristaltic Pump to circulate water internally through the OsteoCool RF Ablation Probe(s) during RF energy delivery. The OsteoCool Pump Cable connects the Osteocool Peristaltic Pump to the OsteoCool RF Generator, which controls the pump speed. The OsteoCool Connector Hub connects the OsteoCool RF Ablation Probe(s) and OsteoCool Thermocouple Monitor(s) to the OsteoCool RF Generator. The OsteoCool Thermocouple Monitor is used with the OsteoCool Thermocouple Monitor Introducer and enables temperature monitoring around the thermal ablation zones during procedures.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Bone
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Physicians familiar with RF lesion techniques
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing has been completed to demonstrate substantial equivalence of the subject OsteoCool™ RF Ablation System to the predicate devices. The system components were subject to the following verification and validation tests, as applicable:
- Mechanical testing: Mechanical verification testing was conducted for the subject OsteoCool™ RF Ablation System to ensure compliance with mechanical requirements of IEC 60601-1: 2005, IEC 60601-2-2: 2009, and self-enforced requirements.
- Electrical testing: Electrical verification testing was conducted for the relevant components of the subject OsteoCool™ RF Ablation System to ensure compliance with current electrical standard requirements.
- Electromagnetic compatibility: Electromagnetic compatibility (EMC) testing was completed for the applicable components of the subject OsteoCool™ RF Ablation System. The results demonstrated compliance of the subject system to current IEC 60601-1-2 standard requirements.
- Biocompatibility: Biocompatibility verification was performed for patient-contacting components of the OsteoCool™ RF Ablation System in accordance with current ISO 10993-1 requirements.
- Thermocouple temperature accuracy: Verification testing demonstrated that the relevant components of the subject OsteoCool™ RF Ablation system achieves accurate temperature measurements as per specified test requirements.
- Usability: Testing was performed to verify and validate the usability requirements of the subject OsteoCool™ RF Ablation System.
- Software: The applicable software verification and validation was completed for the OsteoCool Radiofrequency Generator and OsteoCool Peristaltic Pump based on a Major Level of Concern classification for the devices. FDA's "Guidance for the content of premarket submissions for software contained in Medical Devices" (May-2005) was used to determine the Level of Concern for the devices.
- Comparative bench-top validation testing: Direct comparative bench top validation testing was completed to demonstrate the substantially equivalent ablation performance of the subject device and predicate Uniblate Electrosurgical Device (K080451, S.E. 07/03/2008). The soft tissue model consisted of fresh bovine liver placed in shell of bovine bone. For each test, temperature response curves showing temperature and power over time were generated from procedural data obtained from each respective RF generator. Following lesion formation, the tissue samples were cross-sectioned and lesion dimensions directly measured. The results demonstrated that the lesion dimensions achieved by the subject device are substantially equivalent to those obtained with the predicate device under the same test setup and conditions.
- Impedance Testing: The purpose of this study was to evaluate the performance of OsteoCool in dry (low electrolyte) fresh bovine bone that contained cartilaginous tissue and periosteum, an environment similar to osteoid osteomas. Impedance Testing with dry bovine bone verified that the OsteoCool™ RF Ablation Probe can be used to adequately perform ablations in dry bone, as often seen in Osteoid Osteoma. Impedance tests in patients with osteoid osteoma confirmed that the patient data is similar to the bench testing result with dry bovine bone tissue and the subject device is safe and effective for the intended use. Multiple mitigation measures are adopted to reduce risks related associated with abrupt impedance rise or impedance higher than the preset threshold value.
- Clinical: The purpose of the literature review provided here is to demonstrate the performance and safety of radiofrequency ablation (RFA) to treat Osteoid Osteoma (OO). Performance was assessed using reported outcomes such as technical success, clinical success, changes in pain, and repeat RFA procedures. Safety was conservatively assessed by review of all reported complications regardless of time of onset or reported relatedness to the device/therapy/or procedure. Medtronic's examined both the published use of RFA in OO regardless of manufacturer and irrespective of patient demographic or tumor location and patient outcomes to determine if any new patient risks are created. Medtronic maintains that the potential benefits provided by these devices outweigh the potential risks.
- Pyrogen testing: The OsteoCool™ RF Ablation Kit and OsteoCool Thermocouple Monitor Kit are supplied non-pyrogenic. LAL testing using the Kinetic Chromogenic method will be conducted on every lot to verify that devices are non-pyrogenic. The devices meet current FDA and USP pyrogen limit specifications. All test requirements were met as specified by applicable standards and the test protocols.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4400 Electrosurgical cutting and coagulation device and accessories.
(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
January 15, 2019
Medtronic Sofamor Danek USA, Inc. Ms. Laveeda Leflore Principal Regulatory Affairs Specialist 1800 Pvramid Place Memphis, Tennessee 38132
Re: K182497
Trade/Device Name: OsteoCool RF Ablation System Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical Cutting And Coagulation Device And Accessories Regulatory Class: Class II Product Code: GEI Dated: December 14, 2018 Received: December 17, 2018
Dear Ms. Leflore:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmr/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820)
for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Jennifer R. Stevenson -S3
For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K182497
Device Name OsteoCool™ RF Ablation System
| Indications for Use (Describe) | |
|---|---|
| -------------------------------- | -- |
The OsteoCool™ RF Ablation System is intended for:
- · Palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body.
- Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with
metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy.
· Ablation of benign bone tumors such as osteoid osteoma.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ✓ Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary Medtronic Sofamor Danek USA, Inc.
January 14, 2019
| Submitter | Medtronic Sofamor Danek USA, Inc.
1800 Pyramid Place
Memphis, Tennessee 38132
Telephone: (901) 396-3133
Fax: (901) 346-9738 |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact | Laveeda Leflore
Regulatory Affairs Specialist
Direct Telephone: 901-399-2953
Jeff Sprague
Sr. Regulatory Affairs Program Manager
Direct Telephone: 901-344-1326 |
| Date Prepared | January 14, 2019 |
| Common Name | OsteoCool™ RF Ablation System |
| Regulatory Class | Class II |
| Regulation Number | 21 CFR 878.4400 |
| Regulation Name and Device | Electrosurgical cutting and coagulation device and accessories |
| Product Classification Code | GEI |
| Predicate Devices | OsteoCool® V-3 RF Ablation System
K161949 (S.E. 01/24/2017) – primary predicate
Uniblate Electrosurgical Device
K080451 (S.E. 07/03/2008)
The predicate devices have not been subject to a design related recall. |
Description of Device
The current 510(k) submission is only for a modification to the indications for use of the cleared OsteoCool™ RF Ablation System (K161949). The subject device is identical in all other aspects cleared in OsteoCool® V-3 RF Ablation System (K161949, S.E. 01/24/2017).
4
The OsteoCool™ RF Ablation System includes the following components:
-
- OsteoCool Radiofrequency Generator
-
- OsteoCool RF Ablation Kit:
- i. OsteoCool RF Ablation Probe
- ii. OsteoCool Tube Kit
-
- OsteoCool Thermocouple Kit:
- i. Osteocool Thermocouple Monitor
- ii. Osteocool Thermocouple Monitor Introducer
-
- Osteocool Peristaltic Pump & OsteoCool Pump Cable
-
- OsteoCool Connector Hub
-
- OsteoCool Cart
The OsteoCool™ RF Ablation System delivers controlled radiofrequency (RF) energy in a bipolar manner with a cooling mechanism to facilitate RF lesions in target tissue. The OsteoCool Radiofrequency (RF) Generator operates together with the OsteoCool RF Ablation Probe to deliver the RF energy to the target ablation site(s). The OsteoCool Tube Kit is used with the Osteocool Peristaltic Pump to circulate water internally through the OsteoCool RF Ablation Probe(s) during RF energy delivery. The OsteoCool Pump Cable connects the Osteocool Peristaltic Pump to the OsteoCool RF Generator, which controls the pump speed. The OsteoCool Connector Hub connects the OsteoCool RF Ablation Probe(s) and OsteoCool Thermocouple Monitor(s) to the OsteoCool RF Generator. The OsteoCool Thermocouple Monitor is used with the OsteoCool Thermocouple Monitor Introducer and enables temperature monitoring around the thermal ablation zones during procedures.
Indications for Use:
The OsteoCool™ RF Ablation System is intended for:
· Palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body.
▪ Coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy.
· Ablation of benign bone tumors such as osteoid osteoma.
Comparison to Predicate Devices
5
The indications for use of the subject device represents a modification to the indications for use of the primary predicate OsteoCool V- 3 RF Ablation System (K161949, S.E. 01/24/2017) to enable ablation of benign bone tumors such as osteoid osteoma. The proposed modification to the indications for use does not impact any of these device characteristics because the fundamental scientific technology, principles of operation and mechanism of action, and design and technological aspects is substantially equivalent.
In order to demonstrate substantial equivalence, previously FDA cleared 510(k)s OsteoCool V-3 RF Ablation System (K161949, S.E. 01/24/2017) K161949 (S.E. 01/24/2017) and Uniblate Electrosurgical Device K080451 (S.E. 07/03/2008), which are listed below, in Table 12-1, for the OsteoCool V-3 RF Ablation System are being used as the predicates.
| PREDICATE | PREDICATE | SUBJECT DEVICE | |
|---|---|---|---|
| OsteoCool V-3 RF | Uniblate | OsteoCool TM RF | |
| Ablation System | Electrosurgical | ||
| Device | Ablation System | ||
| (K161949, S.E. | |||
| 01/24/2017) | K080451 (S.E. | ||
| 07/03/2008) | |||
| Class | II | II | Identical |
| Product Code | GEI, 878.4400 | GEI, 878.4400 | Identical |
| PREDICATE | |||
| OsteoCool V-3 RF | |||
| Ablation System | |||
| (K161949, S.E. | |||
| 01/24/2017) | PREDICATE | ||
| Uniblate | |||
| Electrosurgical | |||
| Device | |||
| K080451 (S.E. | |||
| 07/03/2008) | SUBJECT DEVICE | ||
| OsteoCool™ RF | |||
| Ablation System | |||
| Indications for Use | The OsteoCool V-3 | ||
| RF Ablation System | |||
| is intended for: | |||
| Palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body. Coagulation and ablation of tissue during surgical procedures such as palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy. | The AngioDynamics | ||
| Uniblate | |||
| Electrosurgical Device | |||
| is intended for | |||
| coagulation and | |||
| ablation of tissue | |||
| during percutaneous, | |||
| laparoscopic, and | |||
| intraoperative surgical | |||
| procedures such as | |||
| partial or complete | |||
| ablation of non- | |||
| resectable liver | |||
| lesions, osteoid | |||
| osteoma, and | |||
| palliation of pain | |||
| associated with | |||
| metastatic lesions | |||
| involving bone in | |||
| patients who have | |||
| failed or are not | |||
| candidates for | |||
| standard therapy. | The OsteoCool™ RF | ||
| Ablation System is | |||
| intended for: | |||
| Palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body. Coagulation and ablation of tissue during surgical procedures such as palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy. Ablation of benign bone tumors such as osteoid osteoma. | |||
| User | Physicians familiar with | ||
| RF lesion techniques | Physicians familiar | ||
| with RF lesion | |||
| techniques | Identical | ||
| PREDICATE | |||
| OsteoCool V-3 RF | |||
| Ablation System | |||
| (K161949, S.E. | |||
| 01/24/2017) | PREDICATE | ||
| Uniblate | |||
| Electrosurgical | |||
| Device | |||
| K080451 (S.E. | |||
| 07/03/2008) | SUBJECT DEVICE | ||
| OsteoCool™ RF | |||
| Ablation System | |||
| Anatomical site | |||
| of use | Bone | Bone, Soft tissue | Identical to OsteoCool V-3 |
| RF Ablation System | |||
| (K161949, S.E. 01/24/2017) | |||
| Access method | Percutaneous | Percutaneous, | |
| laparoscopic, | |||
| intraoperative | Identical to OsteoCool V-3 | ||
| RF | |||
| Ablation System | |||
| (K161949, S.E. 01/24/2017) | |||
| Energy type | Radiofrequency Energy | Radiofrequency Energy | Identical |
| Principle of | |||
| operation | Operator controlled; RF | ||
| delivered from | |||
| compatible RF generator | Operator controlled; RF | ||
| delivered | |||
| from compatible RF | |||
| generator | Identical | ||
| Mechanism of action | Cellular necrosis | ||
| through thermal | |||
| coagulation | Cellular necrosis through | ||
| thermal | |||
| coagulation | Identical | ||
| Rate of temperature | |||
| rise in sample tissues | Controlled by RF | ||
| generator energy | |||
| output mechanism | Controlled by RF | ||
| generator | |||
| energy output mechanism | Identical | ||
| Feedback | |||
| mechanism | Temperature-controlled | Temperature-controlled | Identical |
| Operating mode | Bipolar RF energy | Monopolar RF energy | Identical to OsteoCool V-3 |
| RF | |||
| Ablation System | |||
| (K161949, S.E. | |||
| 01/24/2017). | |||
| Active | |||
| electrode | |||
| lengths | 7, 10, 20 mm | 1.0 to 3.0 cm (adjustable) | 7, 10, 15, 20 mm (within |
| cleared range of predicate | |||
| K161949) | |||
| Active | |||
| electrode | |||
| material | Stainless steel | Stainless steel | Identical |
| Electrode | |||
| insulation material | Polyimide | Polyimide | Identical |
| PREDICATE | PREDICATE | SUBJECT DEVICE | |
| OsteoCool V-3 RF | |||
| Ablation System | |||
| (K161949, S.E. | |||
| 01/24/2017) | Uniblate | ||
| Electrosurgical | |||
| Device | |||
| K080451 (S.E. | |||
| 07/03/2008) | OsteoCool™ RF | ||
| Ablation System | |||
| Available | |||
| electrode length(s) | 16 cm | 10, 15, 25 cm | Identical to OsteoCool V-3 |
| RF | |||
| Ablation System | |||
| (K161949, S.E. | |||
| 01/24/2017). | |||
| Electrode diameter | 17 Gauge | 17 Gauge | Identical |
| Sterilization | |||
| (Electrode) | EO, Single use | EO, Single use | Identical |
| Compatible | |||
| RF generator | OsteoCool | ||
| Radiofrequency (RF) | |||
| Generator | RITA Medical Systems | ||
| 1500X | |||
| Generator | Identical to OsteoCool V-3 | ||
| RF | |||
| Ablation System | |||
| (K161949, S.E. | |||
| 01/24/2017). | |||
| Other system | |||
| components | Thermocouple monitor | ||
| and introducer, | |||
| peristaltic pump and | |||
| tube kit, connector hub, | |||
| footswitch | Peristaltic pump and | ||
| infusion | |||
| tubing, connector cable, | |||
| grounding pad, | |||
| footswitch | Similar to OsteoCool V-3 | ||
| RF | |||
| Ablation System | |||
| (K161949, S.E. | |||
| 01/24/2017). Subject | |||
| OsteoCool™ RF Ablation | |||
| System does not include the | |||
| optional footswitch. |
Table 5-1: Comparison Table of Predicate and Subject Devices
6
7
8
Performance Testing
Performance testing has been completed to demonstrate substantial equivalence of the subject OsteoCool™ RF Ablation System to the predicate devices. The system components were subject to the following verification and validation tests, as applicable:
Mechanical testing
Mechanical verification testing was conducted for the subject OsteoCool™ RF Ablation System to ensure compliance with mechanical requirements of IEC 60601-1: 2005, IEC 60601-2-2: 2009, and self-enforced requirements.
Electrical testing
9
Electrical verification testing was conducted for the relevant components of the subject OsteoCool™ RF Ablation System to ensure compliance with current electrical standard requirements.
Electromagnetic compatibility
Electromagnetic compatibility (EMC) testing was completed for the applicable components of the subject OsteoCool™ RF Ablation System. The results demonstrated compliance of the subject system to current IEC 60601-1-2 standard requirements.
Biocompatibility
Biocompatibility verification was performed for patient-contacting components of the OsteoCool™ RF Ablation System in accordance with current ISO 10993-1 requirements.
Thermocouple temperature accuracy
Verification testing demonstrated that the relevant components of the subject OsteoCool™ RF Ablation system achieves accurate temperature measurements as per specified test requirements.
Usabilitv
Testing was performed to verify and validate the usability requirements of the subject OsteoCool™ RF Ablation System.
Software
The applicable software verification and validation was completed for the OsteoCool Radiofrequency Generator and OsteoCool Peristaltic Pump based on a Major Level of Concern classification for the devices. FDA's "Guidance for the content of premarket submissions for software contained in Medical Devices" (May-2005) was used to determine the Level of Concern for the devices.
Comparative bench-top validation testing
Direct comparative bench top validation testing was completed to demonstrate the substantially equivalent ablation performance of the subject device and predicate Uniblate Electrosurgical Device (K080451, S.E. 07/03/2008). The soft tissue model consisted of fresh bovine liver placed in shell of bovine bone. For each test, temperature response curves showing temperature and power over time were generated from procedural data obtained from each respective RF generator. Following lesion formation, the tissue samples were cross-sectioned and lesion dimensions directly measured. The results demonstrated that the lesion dimensions achieved by the subject device are substantially equivalent to those obtained with the predicate device under the same test setup and conditions.
Impedance Testing
The purpose of this study was to evaluate the performance of OsteoCool in dry (low electrolyte) fresh bovine bone that contained cartilaginous tissue and periosteum, an environment similar to osteoid osteomas. Impedance Testing with dry bovine bone verified
10
that the OsteoCool™ RF Ablation Probe can be used to adequately perform ablations in dry bone, as often seen in Osteoid Osteoma.
Impedance tests in patients with osteoid osteoma confirmed that the patient data is similar to the bench testing result with dry bovine bone tissue and the subject device is safe and effective for the intended use. Multiple mitigation measures are adopted to reduce risks related associated with abrupt impedance rise or impedance higher than the preset threshold value.
Clinical
The purpose of the literature review provided here is to demonstrate the performance and safety of radiofrequency ablation (RFA) to treat Osteoid Osteoma (OO). Performance was assessed using reported outcomes such as technical success, clinical success, changes in pain, and repeat RFA procedures. Safety was conservatively assessed by review of all reported complications regardless of time of onset or reported relatedness to the device/therapy/or procedure. Medtronic's examined both the published use of RFA in OO regardless of manufacturer and irrespective of patient demographic or tumor location and patient outcomes to determine if any new patient risks are created. Medtronic maintains that the potential benefits provided by these devices outweigh the potential risks.
Pyrogen testing
The OsteoCool™ RF Ablation Kit and OsteoCool Thermocouple Monitor Kit are supplied non-pyrogenic. LAL testing using the Kinetic Chromogenic method will be conducted on every lot to verify that devices are non-pyrogenic. The devices meet current FDA and USP pyrogen limit specifications. All test requirements were met as specified by applicable standards and the test protocols.
Conclusions
Based on the data provided in the premarket notification, the intended use of the subject OsteoCool™ RF Ablation System is substantially equivalent to the predicate devices. The subject and predicate devices share the same fundamental scientific technology, including principles of operation and mechanism of action. Differences in design and technological characteristics between the subject device and predicate Uniblate Electrosurgical Device (K080451, S.E. 07/03/2008) do not raise any new types of questions of safety and effectiveness. The results of verification and validation testing support the substantial equivalence of the subject OsteoCool™ RF Ablation System to the predicate devices.